Strategic Partnerships Certis Oncology has active and recent partnerships with Perceptive Group, Bioemtech, and Provoke Agency, plus a strategic collaboration to advance radiopharmaceutical development. These alliances suggest a receptive environment for co-development, data sharing, and joint ventures that can be leveraged to introduce complementary services and expand market reach.

Platform Opportunity The Oncology Intelligence platform combines predictive AI, agentic data ecosystems, and experimental validation, signaling strong cross-selling potential to biopharma clients seeking an integrated decision intelligence stack for translational oncology research and faster decision-making.

Clinical Validation Axis Patient-derived models and translational validation capabilities highlight a value proposition for sponsors prioritizing functional validation of AI insights, suggesting sales opportunities around translational research services, biomarker discovery, and preclinical model access.

Funding & Growth Signals Recent leadership appointment and notable funding activity, along with a launch of AI/ML platforms in early 2025, indicate a growth phase with increasingly scalable offerings, favorable for upsell discussions around expanded platforms, larger pilot programs, and long-term partnerships.

Mid-Mized Customer Target Company size of 11-50 employees and revenue in the $10M–$25M range place Certis in the mid-market segment, suggesting a target profile for scalable software and services engagements, flexible pricing, and staged adoption of the Oncology Intelligence platform.